泽璟制药：注射用ZGGS18与注射用ZG005及化疗联用临床试验获批

Group 1 - The core point of the article is that Zai Lab (stock code: 688266) has received approval from the National Medical Products Administration for clinical trials of its drugs ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors [1] Group 2 - The approved clinical trial will focus on the use of ZGGS18 and ZG005 in treating patients with advanced solid tumors [1] - This approval marks a significant step for the company in advancing its oncology pipeline [1] - The combination therapy aims to enhance treatment efficacy for patients suffering from late-stage cancer [1]